Shares of Precision BioSciences DTIL rose 0.2% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 157.14% year over year to $0.36, which beat the estimate of ($0.44).
Revenue of $68,805,000 rose by 6282.65% year over year, which beat the estimate of $13,860,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Precision BioSciences hasn't issued any revenue guidance for the time being.
Recent Stock Performance
52-week high: $16.60
Company's 52-week low was at $4.46
Price action over last quarter: Up 11.05%
Company Profile
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segments include Therapeutics and Food.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
